Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 5/20 | 0.67 |
| ▸ | CA12 | O43570 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12703330 | 0.87 | MAP2K1 (0.77) | MAP2K1CA9CA12CA1AR | |
| SCHEMBL14176755 | 0.86 | MAP2K1 (0.75) | MAP2K1CA9CA12ARALDH1A1 | |
| SCHEMBL32688396 | 0.84 | MAP2K1 (0.72) | MAP2K1CA9CA12ARALDH1A1 | |
| SCHEMBL7931393 | 0.83 | MAP2K1 (0.71) | MAP2K1CA9CA12ARALDH1A1 | |
| SCHEMBL12703486 | 0.83 | MAP2K1 (0.71) | MAP2K1CA9CA12ARALDH1A1 | |
| SCHEMBL7560587 | 0.83 | MAP2K1 (0.71) | MAP2K1CA9CA12ARALDH1A1 | |
| SCHEMBL24876966 | 0.82 | MAP2K1 (0.70) | MAP2K1CA9CA12ARALDH1A1 | |
| SCHEMBL29724596 | 0.82 | MAP2K1 (0.70) | MAP2K1CA9CA12CA1AR | |
| SCHEMBL28433664 | 0.82 | MAP2K1 (0.70) | MAP2K1CA9CA12CA1AR | |
| SCHEMBL20870226 | 0.82 | MAP2K1 (0.69) | MAP2K1CA9CA12ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160391-A1 | Substituted Aminopyridines as Fluorescent Reporters for Amide Hydrolases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-24 | — | — | US | disclosed |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| WO-2008008732-A2 | SUBSTITUTED AMINOPYRIDINES AS FLUORESCENT REPORTERS FOR AMIDE HYDROLASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7282575-B2 | Functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | MAP2K1 4727/4885CA9 2364/4885CA12 1995/4885 |
| US-20100160391-A1 | Substituted Aminopyridines as Fluorescent Reporters for Amide Hydrolases | APEH, AADAC, NAALAD2 | MAP2K1 4663/4885CA9 1796/4885CA12 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.